Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

RNA Drug Developer Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate Gene ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at finance.biggo.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

South Korean RNA drug developer Rznomics joined Lilly Gateway Labs in San Diego to accelerate development of RNA editing therapies and expand its global clinical infrastructure and partnerships.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Joining Lilly Gateway Labs opens you direct access to premier US biotech R&D resources and partnerships, shortening RNA therapeutic development and boosting global market entry. Your move is to leverage this access now to ramp up clinical progress and raise your visibility internationally.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechrna-therapiesbiotech-incubationgene-editingglobal-expansionr&d-collaboration